ClinicalTrials.Veeva

Menu
R

Rand Eye Institute | Deerfield Beach, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Aflibercept
UBX1325
GT005
CU06-1004
Foselutoclax
Razuprotafib
CT1812
Zimura
AVD-104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 23 total trials

4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants wit...

Begins enrollment in 1 month
Ramsay Hunt Syndrome
Facial Palsy
Device: BlinkER device.

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: OTX-TKI (axitinib implant)
Drug: Aflibercept

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerab...

Enrolling
Age-Related Macular Degeneration
Drug: Active Comparator CT1812
Drug: Placebo Comparator

Trial sponsors

Kodiak Sciences logo
Bayer logo
U
4
AbbVie logo
Alcon logo
Astellas logo
A
Cognition Therapeutics logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems